Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 4.9% – Time to Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares traded down 4.9% on Tuesday . The stock traded as low as $30.80 and last traded at $30.73. 103,624 shares were traded during mid-day trading, a decline of 85% from the average session volume of 682,991 shares. The stock had previously closed at $32.31.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of recent research reports. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Stock Performance

The stock’s 50 day simple moving average is $33.34 and its 200-day simple moving average is $41.20. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 2.71 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after buying an additional 85,339 shares during the last quarter. State Street Corp grew its holdings in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the period. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the third quarter valued at approximately $97,199,000. Jefferies Financial Group Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $49,290,000. Finally, Geode Capital Management LLC lifted its holdings in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.